Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Themis, MSD ink vaccine agreement
12-18-2019
SHARING OPTIONS:

VIENNA, Austria—A research collaboration and exclusive license agreement was recently struck between Themis Bioscience and MSD (Merck & Co. Inc.) to discover and develop vaccine candidates through the application of Themis' measles virus vector-based platform. Per the agreement, Themis will develop candidates against the undisclosed disease target, with MSD providing research funding as well as development and sales milestone payments worth up to approximately $200 million. MSD will also make an equity investment in Themis, and Themis stands to receive royalties on any approved products that result from this deal.
 
“At MSD, we continue to evaluate technologies with the potential to deliver novel vaccine candidates,” said Dr. Daria Hazuda, chief scientific officer, Exploratory Science Center and vice president of infectious diseases and vaccine discovery at MSD. “We look forward to collaborating with the scientists at Themis.”
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.